Viewing nowCombinationJanuritine Combo Extended-Release Tablet 50/750 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 750mg
Tablet · Prescription medication · Combination
Dae Won Pharmaceutical Co., Ltd.

MFDS item code 202300021 · Approved 2023.01.02 · Insurance code 671807620
Improves blood glucose control in patients with type 2 diabetes
This medication is used to help control blood sugar levels in patients with type 2 diabetes. In particular, the combination of sitagliptin and metformin is effective in improving blood sugar levels, especially when used in conjunction with dietary and exercise regimens.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg, 50/750 mg, or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their existing metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined in consideration of the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately.
This medication is composed of sitagliptin and metformin and is used for the treatment of diabetes. First, sitagliptin may rarely cause serious allergic reactions; if symptoms such as rash, hives, or difficulty in breathing occur, discontinue use immediately and consult a physician. Additionally, sitagliptin can potentially trigger acute pancreatitis, and symptoms such as abdominal pain, vomiting, or nausea should be reported to medical personnel immediately. Metformin can cause a rare but life-threatening adverse effect known as lactic acidosis; thus, if sudden shortness of breath, muscle pain, fatigue, or abdominal pain occur, discontinue the medication and visit a hospital immediately. This medication should not be administered to patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, severe infections, or dehydration. If tests using contrast agents for imaging studies are planned, this medication should be discontinued during that period, and it should be resumed only after confirming normal kidney function. This medication is not recommended for use in pregnant women or women who may become pregnant, nor in nursing mothers. There is a risk of hypoglycemia while taking this medication; therefore, regular meals should be observed, and sudden exercise or skipping meals should be avoided. Extra caution is necessary when used with other glucose-lowering agents. Also, alcohol consumption can increase the risk of lactic acidosis, so it should be avoided while taking this medication. For those undergoing surgery, this medication should be discontinued 48 hours prior to the operation and should only be resumed after confirming that oral intake has normalized and kidney function is stable. Gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain may occur while using this medication, and patients should consult a physician if these symptoms are severe. Regular monitoring of kidney function and blood tests are necessary to check for vitamin B12 deficiency due to metformin. Elderly patients or those with decreased kidney function may require dosage adjustments and more frequent monitoring of kidney function. If any unusual symptoms or suspected adverse effects occur while taking this medication, medical personnel should be notified immediately, and the medication should not be discontinued or the dose altered arbitrarily.
Hypersensitivity, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevation of liver enzymes, acute renal failure, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, at room temperature between 1 to 30 degrees Celsius. Therefore, it is important to keep it away from direct sunlight and maintain an appropriate temperature to preserve its efficacy.
Bright green oval-shaped extended-release film-coated tablet with both sides convex
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 750mg
Tablet · Prescription medication · Combination
Dae Won Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.